Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity
作者:Can-Hui Zheng、Hui Yang、Meng Zhang、Shi-Hai Lu、Duo Shi、Juan Wang、Xiu-Hua Chen、Xiao-Hui Ren、Jia Liu、Jia-Guo Lv、Ju Zhu、You-Jun Zhou
DOI:10.1016/j.bmcl.2011.11.101
日期:2012.1
than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-xL, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins
在比较Bim BH3:Bcl-x L络合物和ABT-737:Bcl-x L络合物的结构的基础上,设计了一系列A类化合物。这些化合物具有ABT-737的基本骨架和Bim BH3的h2残基。在饱和诱变测定中,这些残基已显示出与Bim BH3的广谱结合特性有关。与作为Bcl-2蛋白家族抗凋亡成员的选择性抑制剂的ABT-737不同,A类化合物对目标蛋白具有广谱结合活性,类似于Bim BH3肽。然后通过修饰最有效的A类化合物的结构来合成B类化合物化合物A - 4。这些大多数B类化合物显示出比A类化合物更好的与靶蛋白的结合亲和力。他们还显示出比ABT-737更有效地抑制已知以高水平表达Bcl-x L,Bcl-2和Mcl-1蛋白的多种肿瘤细胞的生长。在我们生产的所有化合物中,化合物B - 11和B - 12具有最强的抗肿瘤活性。这项研究表明,根据Bim BH3的结构设计小分子抑制剂是可行的,该结构显示了与Bcl-x